Edwards Lifesciences Corporation (NYSE:EW) Receives $96.14 Average Price Target from Analysts

Shares of Edwards Lifesciences Corporation (NYSE:EW) have earned an average rating of “Moderate Buy” from the twenty-seven analysts that are currently covering the stock, Marketbeat Ratings reports. Nine research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have given a strong buy rating to the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $96.1364.

Several brokerages have commented on EW. Mizuho increased their target price on Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. TD Cowen upgraded Edwards Lifesciences from a “hold” rating to a “buy” rating in a report on Friday, January 9th. UBS Group restated a “neutral” rating and set a $94.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 4th. Raymond James Financial upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price on the stock in a report on Monday, November 3rd. Finally, Jefferies Financial Group set a $98.00 price target on Edwards Lifesciences and gave the company a “buy” rating in a research note on Wednesday, October 29th.

Insider Transactions at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 1,019 shares of Edwards Lifesciences stock in a transaction dated Friday, January 9th. The stock was sold at an average price of $85.70, for a total transaction of $87,328.30. Following the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,885,571.40. The trade was a 4.43% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 7,700 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $84.47, for a total transaction of $650,419.00. Following the transaction, the chief financial officer directly owned 39,898 shares in the company, valued at $3,370,184.06. This represents a 16.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 43,804 shares of company stock valued at $3,699,082 over the last quarter. 1.29% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Edwards Lifesciences

Large investors have recently bought and sold shares of the business. Econ Financial Services Corp bought a new stake in shares of Edwards Lifesciences during the 2nd quarter worth approximately $889,000. Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in Edwards Lifesciences by 7.0% in the third quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 137,835 shares of the medical research company’s stock worth $10,719,000 after purchasing an additional 9,069 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Edwards Lifesciences by 13.2% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 86,235 shares of the medical research company’s stock worth $6,706,000 after purchasing an additional 10,078 shares during the period. Atlantic Union Bankshares Corp lifted its position in shares of Edwards Lifesciences by 2,240.9% during the third quarter. Atlantic Union Bankshares Corp now owns 11,892 shares of the medical research company’s stock worth $925,000 after purchasing an additional 11,384 shares during the last quarter. Finally, Arkadios Wealth Advisors purchased a new stake in shares of Edwards Lifesciences during the second quarter valued at $300,000. Institutional investors own 79.46% of the company’s stock.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $78.83 on Friday. The company has a market capitalization of $45.75 billion, a price-to-earnings ratio of 43.08, a price-to-earnings-growth ratio of 2.06 and a beta of 0.94. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00. Edwards Lifesciences has a one year low of $65.94 and a one year high of $87.89. The company’s 50-day moving average is $82.87 and its 200 day moving average is $81.02.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 10th. The medical research company reported $0.58 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.62 by ($0.04). The firm had revenue of $1.57 billion during the quarter, compared to analysts’ expectations of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The firm’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period last year, the firm posted $0.59 earnings per share. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Sell-side analysts expect that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.